Objective: Research and clinical translation in schizophrenia is limited by inconsistent
definitions of treatment resistance and response. To address this issue, the authors …

Empirical evidence indicates a significant bidirectional association between mental
disorders and physical diseases, but the prospective impact of mental disorders on clinical …

Background Emraclidine is a novel, brain-penetrant, highly selective M4 receptor positive
allosteric modulator in development for the treatment of schizophrenia. We aimed to …

The goal of this guideline is to improve the quality of care and treatment outcomes for
patients with schizophrenia, as defined by the Diagnostic and Statistical Manual of Mental …

Clinical practice guidelines (CPGs) translate evidence into recommendations to improve
patient care and outcomes. To provide an overview of schizophrenia CPGs, we conducted a …

Importance The effectiveness of antipsychotic polypharmacy in schizophrenia relapse
prevention is controversial, and use of multiple agents is generally believed to impair …

The long‐term benefit‐to‐risk ratio of sustained antipsychotic treatment for schizophrenia
has recently been questioned. In this paper, we critically examine the literature on the long …

Schizophrenia is a debilitating illness with a lifetime prevalence estimate of 0.6% and
consists of symptoms from the positive, negative, and cognitive domains. Social support …

METHODS A group of 8 experts on the management of schizophrenia and LAIs met to
evaluate the evidence and to develop a set of recommendations regarding the clinical use …

Importance Long-acting injectable antipsychotics (LAIs) can potentially reduce
hospitalization risk by enhancing medication adherence but are rarely considered for early …